Spinal chemotherapy may block deadly brain cancer spread
NCT ID NCT07511725
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether adding a chemotherapy drug (thiotepa) directly into the spinal fluid can prevent glioblastoma from spreading to the brain and spinal cord lining. The study enrolls 38 newly diagnosed patients whose tumors touch brain fluid spaces or whose surgery accidentally opened those spaces. Participants receive standard treatment plus six weekly spinal injections of thiotepa, and researchers will track survival and side effects for two years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
thiotepa (chemotherapy given into the spinal fluid)
What this could lead to
If it works, this could reduce the risk of cancer spreading in the brain and spinal cord lining, potentially extending survival for glioblastoma patients.
What could go wrong
This is a small, early-phase pilot study with only 38 participants, so results may not apply broadly. Adding chemotherapy to the spine carries risks like infection, bleeding, or nerve damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA (GBM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
2nd Affiliated Hospital, School of Medicine
RECRUITINGHangzhou, Zhejiang, 310000, China
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••